Cryolipolysis Body Contouring — Moderate for short-term local fat-layer and circumference reduction, pooled across two…

Cryolipolysis, widely recognized by the brand name CoolSculpting, is a noninvasive body-contouring procedure that uses controlled cooling to target one localized bulge of subcutaneous fat at a time. An applicator draws the tissue in with gentle vacuum suction and holds it at a low temperature for roughly 35 to 60 minutes per cycle. Fat cells are more sensitive to cold than the surrounding skin, nerve, and muscle tissue, so the cooling injures a share of the fat cells in the cooled area while the overlying skin stays intact. The body clears the affected cells gradually over the following weeks, and the fat layer in that area becomes thinner. This is an aesthetic device category, not a recovery modality. It is offered by some recovery studios, med spas, and aesthetic clinics as an add-on to a wellness menu, and it is listed here for reference rather than as an endorsement. Devices in this class have been cleared in the United States since 2010 for noninvasive subcutaneous fat reduction, and the current generation is marketed for roughly nine body areas including the abdomen, flanks, thighs, upper arms, back and bra area, and the submental area under the chin. It is important to be clear about what it does not do. It reduces the thickness of a specific fat layer; it does not change body weight in any pooled analysis, does not tighten skin, does not build muscle, and is not a substitute for nutrition, training, or medical care for obesity. Most areas need more than one cycle, results are assessed over 8 to 16 weeks, and a portion of clients see little visible change.

How cryolipolysis body contouring works

Adipocytes are injured by cold at higher temperatures than skin, nerve, and muscle tissue. Cryolipolysis uses that difference: the applicator holds the target area at a controlled low temperature long enough to damage a share of the fat cells in the cooled tissue without harming the skin above it. Those cells are cleared gradually through a local inflammatory response over the following weeks, which is why the fat layer thins over months rather than immediately. Pooled evidence points in a consistent direction for local measures. A 2025 systematic review and meta-analysis in Obesity Reviews, covering 30 studies and 3,158 participants, reported at 12 weeks a mean abdominal circumference reduction of 3.56 cm, a suprailiac fat-thickness reduction of 5.22 mm, a BMI reduction of 1.80, and pooled satisfaction of about 80 percent. A separate 2025 meta-analysis of 10 studies and 285 participants found a mean fat-thickness reduction of 3.56 mm and a circumference reduction of 3.45 cm, while the pooled change in body weight was not statistically significant. A smaller 2025 review of 8 submental studies and 206 participants reported an average 2.78 mm reduction in under-chin fat thickness. The limitations matter as much as the effects. Most included studies were single-arm or nonrandomized, control groups were rare, statistical heterogeneity was very high (I-squared above 80 percent for several pooled outcomes), follow-up rarely extended past six months, and long-term maintenance is largely unstudied. Minor adverse effects are the norm rather than the exception: across pooled data, numbness was reported by roughly half of participants and redness, swelling, pain, and sensitivity each by a quarter to nearly half. Paradoxical adipose hyperplasia, in which the cooled area gradually enlarges and firms instead of shrinking, was pooled at 0.22 percent across 28 studies and 13,078 patients, meaningfully above the roughly 0.03 percent rate quoted by the device manufacturer, with a mean onset around 16 months and generally requiring a surgical correction.